Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
Labcorp announced the nationwide availability of the VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved IHC companion diagnostic for PTEN protein loss in prostate adenocarcinoma. The test helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP in combination with other therapies, addressing an unmet need in prostate cancer care.
Key figures
- Employees
- 71000
- Tests performed annually
- 750000000
- Fda drugs supported percent
- 85
- New prostate cancer cases annually
- 330000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.